Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
oleh: Line Lundegaard Bang, Lone Wulff Madsen, Rune Micha Pedersen, Anna Christine Nilsson, Isik Somuncu Johansen, Thomas Emil Andersen
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-09-01 |
Deskripsi
Subjek
Neutralizing antibodies; Monoclonal antibodies; Sotrovimab; In vitro neutralization; SARS-CoV-2; COVID-19